Business Wire

Ant International President Highlights AI and Connectivity as Key SME Growth Drivers

12.3.2025 12:19:00 CET | Business Wire | Press release

Share

Artificial Intelligence (AI) is being converted into flexible cross-border payment and digitisation solutions to help SMEs raise efficiency, lowering costs and controlling risks.More industry collaborations are needed to bridge payment systems and tech know-how.

Digital payment innovations are increasingly powerful tools for global businesses to raise productivity and turbocharge growth. The Digital Payment Market size1 is expected to grow at a CAGR of 11.8% and reach US$193.7 billion. However, there are digital divides and silos abound in core financial services for the global commerce system, especially in cross-border online and offline digital payment and settlement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312187829/en/

Douglas Feagin (left), President of Ant International, discussed payments innovation at GFTN Forum Japan in March 2025. (Photo: Business Wire)

“Even as technology advances in leaps and bounds, small businesses continue to face challenges in today’s digitised international transactions, from cross-border payment to cross-market growth,” said Douglas Feagin, President of Ant International, during the GFTN Forum held during the Japan Fintech Festival in Japan in March 2025. “We need to convert exciting developments in foundational technologies, such as AI, into comprehensive, effective and affordable solutions for the world’s long-tail business community.”

Ant International’s flagship Alipay+ cross-border mobile payment and digitisation technology has expanded to support 36 international payment apps, connecting over 90 million merchants across 66 markets. This “invisible” technology behind the cash register enables merchants to receive cross-border payments seamlessly and securely from individuals using their home e-wallets while maintaining competitive foreign exchange rates.

Interoperability is key, as local SMEs should be able to accept international payments more easily. In Asia, initiatives like national QRs have greatly boosted connectivity, and Alipay+ helps to bridge these infrastructures with our global payment partner users, but more needs to be done to bring together card and wallet-based ecosystems, Feagin said.

For SMEs, the capacity to accept various forms of international payments is not merely an advantage; it has become an essential factor for survival and growth in an increasingly competitive marketplace, Feagin noted.

Artificial Intelligence (AI) technology is crucial in addressing these pressing needs by providing tools that help SMEs make informed decisions swiftly, ensuring they meet customer demands while minimizing operational risks. A recent McKinsey report2 for 2025 underscores this importance, indicating that 92% of businesses plan to increase their AI investments this year. The consulting firm earlier predicted that companies integrating AI into their financial operations can expect productivity increases of up to 25%3.

At Ant International, AI-powered solutions are being developed to forecast currency demands based on transaction flows, enhancing efficiency in foreign exchange processes and steering the industry towards real-time payment systems.

For instance, Ant International’s AI-driven solution can forecast customers’ foreign-exchange needs with more than 90% accuracy based on provided data, which enables the company to help customers optimise their FX strategies.

As financial fraud becomes increasingly sophisticated, AI is paramount in safeguarding transactions. Ant International’s AI-powered risk management capabilities can effectively implement advanced fraud detection mechanisms that analyse patterns, identify anomalies, and protect against potential threats.

Interoperability will continue to be enhanced, particularly in Asia, where national QR systems and mobile wallets facilitate seamless transactions. This trend is expected to evolve rapidly as new LLM models are developed, enabling companies to streamline these workflows, said Feagin.

“We expect this revolution to continue at a rapid pace, and AI to accelerate efficiency and provide solutions for our customers,” added Feagin.

1https://www.marketsandmarkets.com/Market-Reports/digital-payment-market-209834053.html
2https://www.mckinsey.com/capabilities/mckinsey-digital/our-insights/superagency-in-the-workplace-empowering-people-to-unlock-ais-full-potential-at-work
3https://psico-smart.com/en/blogs/blog-how-can-artificial-intelligence-enhance-productivity-management-in-the-workplace-88579

View source version on businesswire.com: https://www.businesswire.com/news/home/20250312187829/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye